litlas
ログインアカウント作成

Ji‐Youn Han

1999–2025 年に発表

別表記
Ji Youn Han · Ji-Youn Han
117
論文数
22,658
被引用数
65
h 指数
108
i10 指数

被引用数

Ji‐Youn Han の年別被引用数1993 年: 被引用 1 件1999 年: 被引用 2 件2000 年: 被引用 8 件2001 年: 被引用 18 件2002 年: 被引用 24 件2003 年: 被引用 20 件2004 年: 被引用 10 件2005 年: 被引用 13 件2006 年: 被引用 18 件2007 年: 被引用 33 件2008 年: 被引用 39 件2009 年: 被引用 48 件2010 年: 被引用 38 件2011 年: 被引用 34 件2012 年: 被引用 57 件2013 年: 被引用 59 件2014 年: 被引用 65 件2015 年: 被引用 75 件2016 年: 被引用 136 件2017 年: 被引用 254 件2018 年: 被引用 303 件2019 年: 被引用 997 件2020 年: 被引用 1,227 件2021 年: 被引用 1,358 件2022 年: 被引用 1,040 件2023 年: 被引用 791 件2024 年: 被引用 1,310 件2025 年: 被引用 718 件2026 年: 被引用 17 件1994〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,529 件、この内訳の 20.9%中国: 引用元論文 1,850 件、この内訳の 15.3%日本: 引用元論文 778 件、この内訳の 6.4%イタリア: 引用元論文 733 件、この内訳の 6%フランス: 引用元論文 581 件、この内訳の 4.8%イギリス: 引用元論文 525 件、この内訳の 4.3%韓国: 引用元論文 494 件、この内訳の 4.1%スペイン: 引用元論文 491 件、この内訳の 4%ドイツ: 引用元論文 485 件、この内訳の 4%カナダ: 引用元論文 407 件、この内訳の 3.4%オランダ: 引用元論文 297 件、この内訳の 2.4%オーストラリア: 引用元論文 282 件、この内訳の 2.3%
0%20.9%その他 22.1%

機関

分野

  • Medicine78.8%
  • Biochemistry, Genetics and Molecular Biology15.9%
  • Immunology and Microbiology2.2%
  • Engineering0.5%
  • Neuroscience0.4%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • その他1.8%

トピック

  • Cancer Immunotherapy and Biomarkers14.9%
  • Lung Cancer Treatments and Mutations14.7%
  • Lung Cancer Research Studies8.4%
  • Lung Cancer Diagnosis and Treatment5.5%
  • Cancer Genomics and Diagnostics3.3%
  • Immunotherapy and Immune Responses2.5%
  • その他50.7%

共著者

全論文

検索で開く
  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

    著者: Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon - The Lancet 2015 被引用: 6,537

  2. Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

    著者: Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist - New England Journal of Medicine 2020 被引用: 997

  3. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

    著者: Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji‐Youn Han, Sang‐We Kim, Chee Khoon Lee, Joshua K. Sabari, Alexander I. Spira, Tsung‐Ying Yang, Dong‐Wan Kim, Ki Hyeong Lee, Rachel E. Sanborn, José Trigo, Kōichi Goto, Jong‐Seok Lee, James Chih‐Hsin Yang, Ramaswamy Govindan, Joshua Bauml, Pilar Garrido, Matthew Krebs, Karen L. Reckamp, John Xie, Joshua C. Curtin, Nahor Haddish‐Berhane, Amy Roshak, Dawn Millington, Patricia Lorenzini, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho - Journal of Clinical Oncology 2021 被引用: 632

  4. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    著者: Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le - New England Journal of Medicine 2020 被引用: 854

  5. Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

    著者: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee‐Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Angelo Delmonte, Rosario García Campelo, Dong‐Wan Kim, Alessandra Bearz, Frank Griesinger, Alessandro Morabito, Enriqueta Felip, Raffaele Califano, Sharmistha Ghosh, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Neeraj Gupta, J. Haney, David Kerstein, Sanjay Popat - New England Journal of Medicine 2018 被引用: 976

  6. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    著者: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, M.R. García Campelo, Dong‐Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Huamao Mark Lin, Yuyin Liu, Florin Vranceanu, Huifeng Niu, Pingkuan Zhang, Sanjay Popat - Journal of Thoracic Oncology 2021 被引用: 372

  7. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

    著者: Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Ji‐Youn Han, Nobuyuki Katakami, Hye Ryun Kim, Rachel Hodge, Paramjit Kaur, Andy Brown, Dana Ghiorghiu, Vassiliki A. Papadimitrakopoulou, Tony Mok - Journal of Clinical Oncology 2018 被引用: 515

  8. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

    著者: Ryan J. Hartmaier, Aleksandra Markovets, Myung‐Ju Ahn, Lecia V. Sequist, Ji‐Youn Han, Byoung Chul Cho, Helena A. Yu, Sang‐We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, С. В. Орлов, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne - Cancer Discovery 2022 被引用: 154

  9. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    著者: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas - Journal of Thoracic Oncology 2021 被引用: 312

  10. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

    著者: Juliann Chmielecki, Tony Mok, Yi‐Long Wu, Ji‐Youn Han, Myung‐Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih‐Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki A. Papadimitrakopoulou - Nature Communications 2023 被引用: 173

  11. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

    著者: Sehhoon Park, Tae Min Kim, Ji‐Youn Han, Gyeong‐Won Lee, Byoung Yong Shim, Yun‐Gyoo Lee, Sang‐We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki Hyeong Lee, Eun Joo Kang, Ju Won Kim, Seong Hoon Shin, Chan‐Young Ock, Byung‐Ho Nam, Jaebong Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn - Journal of Clinical Oncology 2023 被引用: 164

  12. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

    著者: Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han, Myung‐Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Seung‐Whan Kim, Frances A. Shepherd, Janessa Laskin, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Wu‐Chou Su, Thomas John, Martin Sebastian, Helen Mann, Michele Miranda, Gianluca Laus, Yuri Rukazenkov, Yi‐Long Wu - Annals of Oncology 2020 被引用: 276

  13. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

    著者: Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, Sergey Orlov, Mireille Cantarini, Remy B. Verheijen, Anders Mellemgaard, Lone H. Ottesen, Paul Frewer, Xiaoling Ou, Geoffrey R. Oxnard - The Lancet Oncology 2020 被引用: 413

  14. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

    著者: Byoung Chul Cho, Dong‐Wan Kim, Alexander I. Spira, Jorge Gómez, Eric B. Haura, Sang‐We Kim, Rachel E. Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom, Jong Seok Lee, Ji‐Youn Han, Misako Nagasaka, Joshua K. Sabari, Sai‐Hong Ignatius Ou, Patricia Lorenzini, Joshua Bauml, Joshua C. Curtin, Amy Roshak, Grace Gao, John Xie, Meena Thayu, Roland E. Knoblauch, Keunchil Park - Nature Medicine 2023 被引用: 101

  15. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

    著者: Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna Minchom, Melina E. Marmarelis, Rachel E. Sanborn, James Chih‐Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I. Spira, Se‐Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji‐Youn Han, Mariam P. Alexander, Rohit Joshi, Enriqueta Felip, Pei Jye Voon, Pongwut Danchaivijitr, Ping‐Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K. Sabari, Angel Qin, Dariusz M. Kowalski, Mehmet Alı Nahıt Şendur, John Xie, Debopriya Ghosh, Ali Alhadab, Nahor Haddish‐Berhane, Pamela L. Clemens, Patricia Lorenzini, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro, for the PALOMA-3 Investigators, Hiroaki Akamatsu, Mariam P. Alexander, Annalen Bleckmann, Federico Cappuzzo, Ying Cheng, Byoung Chul Cho, Timuçin Çil, Alexis B. Cortot, Pongwut Danchaivijitr, Till‐Oliver Emde, Dilek Erdem, Enriqueta Felip, F. Estevinho, Maria Lurdes Ferreira, Flavio Ferreira da Silva, Maria Campelo, Laurent Greillier, Alastair Greystoke, Ji‐Youn Han, Ping‐Chih Hsu, Jen‐Yu Hung, Mei Ji, Thomas John, Rohit Joshi, Young‐Chul Kim, Masashi Kondo, Ernesto Korbenfeld, Dariusz M. Kowalski, Se‐Hoon Lee, Natasha B. Leighl, Juan Li, Sheng-Hao Lin, Baogang Liu, Caigang Liu, John Seng-Hooi Low, Melina E. Marmarelis, Bartomeu Massutí, Anna R. Minchom, Sara Moore, Mor Moskovitz, Adnan Nagrial, Danny Nguyen, Silvia Novello, Y. Ohe, Mustafa Özgüroğlu, Özgür Özyılkan, Antonio Passaro, Nir Peled, Naiyarat Prasongsook, Angel Qin, Elisa F. Ramos ほか 22 名 - Journal of Clinical Oncology 2024 被引用: 114

  16. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    著者: Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark ほか 52 名 - The Lancet Oncology 2018 被引用: 576

  17. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

    著者: Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee‐Chen Chang, Lucio Crinò, Miyako Satouchi, Quincy S. Chu, Toyoaki Hida, Ji‐Youn Han, Óscar Juan, Frank Dunphy, Makoto Nishio, Jin‐Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi - The Lancet Oncology 2016 被引用: 643

  18. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    著者: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, M.R. García Campelo, Dong‐Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Huamao Mark Lin, Neeraj Gupta, Michael J. Hanley, Quanhong Ni, Pingkuan Zhang, Sanjay Popat - Journal of Clinical Oncology 2020 被引用: 367

  19. Direct isolation and characterization of circulating exosomes from biological samples using magnetic nanowires

    著者: Jiyun Lim, Mihye Choi, Hyungjae Lee, Young-Ho Kim, Ji‐Youn Han, Eun Sook Lee, Youngnam Cho - Journal of Nanobiotechnology 2019 被引用: 198

  20. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

    著者: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, José Luis Perez‐Gracia, Ji‐Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Zsuzsanna Szalai, Matthew A. Gubens, Wu‐Chou Su, Giovanni Luca Ceresoli, Ayman Samkari, Erin Jensen, Gregory M. Lubiniecki, Paul Baas - Journal of Clinical Oncology 2020 被引用: 281

  21. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

    著者: D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor–Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope A. Bradbury, Mor Moskovitz, Nuran Katgı, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji‐Youn Han, Shang‐Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih‐Hsi S. Kuo, Kazumi Nishino, Se‐Hoon Lee, David Planchard, Christina S. Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine K. Ratajczak, Shun Lü - Journal of Clinical Oncology 2024 被引用: 135

  22. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

    著者: Myung‐Ju Ahn, Chao‐Hua Chiu, Ying Cheng, Ji‐Youn Han, Sarah B. Goldberg, Alastair Greystoke, Jeffrey Crawford, Yanqiu Zhao, Xiangning Huang, Martin Johnson, Karthick Vishwanathan, James Yates, Andy Brown, Ariadna Mendoza‐Naranjo, Tony Mok - Journal of Thoracic Oncology 2019 被引用: 169

  23. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    著者: Ross A. Soo, Ji‐Youn Han, Urania Dafni, Byoung Chul Cho, Chong Ming Yeo, Ernest Nadal, Enric Carcereny, J. de Castro, María Ángeles Sala, Reyes Bernabé, Linda Coate, M. Provencio Pulla, Rosario García Campelo, Sinéad Cuffe, Sayed M.S. Hashemi, Martin Früh, Bartomeu Massutí, José García-Sánchez, Manuel Dómine, Margarita Majem, J.M. Sánchez-Torres, Christian Britschgi, Miklos Pless, Georgia Dimopoulou, Heidi Roschitzki‐Voser, Barbara Ruepp, Rafael Rosell, Rolf A. Stahel, Solange Peters, Rolf A. Stahel, Solange Peters, Ross A. Soo, Ji‐Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki‐Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne‐Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki‐Voser, Susanne Roux, Barbara Ruepp, Magdalena Sánchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, M. Reist, Priska Rentsch, Linda Coate, Sinéad Cuffe, Sayed M.S. Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario García Campelo, Bartomeu Massutí, José López García, Manuel Dómine, Margarita Majem, José Miguel Sánchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross A. Soo, Chong Ming Yeo, Ji‐Youn Han, Byoung Chul Cho - Annals of Oncology 2021 被引用: 116

  24. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

    著者: Myung‐Ju Ahn, Ji‐Youn Han, Ki Hyeong Lee, Sang-We Kim, Dong‐Wan Kim, Yun‐Gyoo Lee, Eun Kyung Cho, Joo-Hang Kim, Gyeong‐Won Lee, Jong Seok Lee, Young Joo Min, Jin-Soo Kim, Sung Sook Lee, Hye Ryun Kim, Min Hee Hong, Jin Seok Ahn, Jong‐Mu Sun, Heung Tae Kim, Ki Hyeong Lee, Sohee Kim, Byoung Chul Cho - The Lancet Oncology 2019 被引用: 135